CARM · As filed with the SEC
Carisma Therapeutics income statement, by quarter
The statement as Carisma Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Unaudited Consolidated Statements of Operations and Comprehensive Loss · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024† 3 months ended Dec 31, 2024 | Q3 2024 3 months ended Sep 30, 2024 |
|---|---|---|---|---|---|
| Collaboration revenues | 45,250,000 | 0 | 3,729,000 | — | 3,385,000 |
| Operating expenses: | |||||
| Research and development | 197,000 | 2,424,000 | 9,156,000 | — | 11,326,000 |
| General and administrative | 1,239,000 | 3,354,000 | 3,907,000 | — | 5,203,000 |
| Total operating expenses | 1,436,000 | 5,778,000 | 13,063,000 | — | 16,529,000 |
| Operating loss | 43,814,000 | (5,778,000) | (9,334,000) | — | (13,144,000) |
| Change in fair value of derivative liability | — | — | — | 0† | 0 |
| Interest income, net | — | — | 68 | 220† | 442 |
| Gain (loss) on sale of held for sale assets | 320,000 | (3,539,000) | — | — | — |
| Loss on abandonment of operating lease right-of-use asset | 0 | (927,000) | — | — | — |
| Other income, net | 583,000 | 470,000 | — | — | — |
| Pre-tax income(loss) | 44,717,000 | (9,774,000) | (9,266,000) | — | (12,702,000) |
| Income tax expense | 0 | 0 | 0 | — | 0 |
| Net income(loss) | 44,717,000 | (9,774,000) | (9,266,000) | — | (12,702,000) |
| Share information: | |||||
| Net income (loss) per share of common stock, basic (in dollars per share) | 1.07 | (0.23) | (0.22) | — | (0.31) |
| Net income (loss) per share of common stock, diluted (in dollars per share) | 1.07 | (0.23) | (0.22) | — | (0.31) |
| Weighted-average shares of common stock outstanding, basic (in shares) | 41,788,096 | 41,788,096 | 41,771,213 | — | 41,588,035,000 |
| Weighted-average shares of common stock outstanding, diluted (in shares) | 41,940,292 | 41,788,096 | 41,771,213 | — | 41,588,035,000 |
| Net loss | — | — | — | (17,635)† | (12,702) |
| Unrealized gain on marketable securities | — | — | — | 0† | 0 |
| Comprehensive loss | — | — | — | (17,635)† | (12,702) |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.